[Clinical restenosis in diabetic patients treated with drug eluting stents for de novo lesions].
We evaluated immediate and mid-term clinical and angiographic results in diabetic patients with percutaneous coronary intervention with deployment of drug eluting stents. Between November of 2004 and June of 2005 percutaneous coronary interventions were performed 860 with the deployment of 112 drug eluting stents to 42 diabetic patients. The mean of stents was 2.6 per patient, and the type of drug eluting stent was paclitaxel in 60% and sirolimus in 40%. The average of age was 51.2 +/- 9.6 years old. The gender was male in 25 (60%) of patients and female in 17 (40%). The indication of coronary angiography was unstable angina in 15 (35%) patients and stable angina in 27 (65%). There was history of anterior myocardial infarction in 20 (47%), inferior myocardial infarction in 8 (20%) and multiple vessel disease in 16 (38%). The stenosis severity of the lesion was 85.9% +/- 12.2% and the left ventricular function was (55 +/- 10). The hospital stay was 7 +/- 5.4 days. Both clinical and angiographic immediate success was 100%. The average follow was 7.6 +/- 3.3 months in 34 patients (80.9%). The target lesion revascularization (TLR) was 7.1%. (3 patients). Death, myocardial infarction or reinfarction (0%). One patient (2.3%) developed contrast induced nephropathy. These results suggest that the use of drug eluting stents (paclitaxel or sirolimus) in diabetic patients has a high rate of success with good angiographic and clinical results and with a low rate of complications or restenosis in this high risk group of patients.